| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss before income taxes | -34,401 | -48,925 | -43,451 | -23,582 |
| Income tax benefit (expense) | -1,054 | 1,015 | 392 | 91 |
| Net loss | -33,347 | -49,940 | -43,843 | -23,673 |
| Unrealized income (loss) on investments | 17 | -8 | -42 | 267 |
| Comprehensive loss | -33,330 | -49,948 | -43,885 | -23,406 |
| Basic and diluted loss per ordinary share (in dollars per share) | -0.69 | -1.05 | -0.92 | -0.55 |
| Weighted-average number of ordinary shares (in shares) | 48,057,386 | 47,739,816 | 47,422,119 | 43,100,237 |
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)